Results 41 to 50 of about 1,266 (177)

Treatable traits, combination inhaler therapy and the future of asthma management

Respirology, Volume 28, Issue 9, Page 828-840, September 2023., 2023
Abstract The landscape of asthma has considerably changed in the last decade. Effective medications and inhaler devices have been developed and integrated into the asthma pharmacopoeia, but unfortunately, the proportion of uncontrolled patients remains unacceptably high. This is now recognized to be mainly due to the inappropriate use of medications or
Peter G. Gibson, Vanessa M. McDonald, Dennis Thomas   +2 more
wiley   +1 more source

Dried blood spots for doping controls—Development of a comprehensive initial testing procedure with fully automated sample preparation

Biomedical Chromatography, Volume 37, Issue 8, August 2023., 2023
Abstract Currently, primarily urine, whole blood and serum samples are analyzed for doping‐relevant substances in professional sports, but recently dried blood spots (DBS) have been introduced as complementary matrix, offering advantageous features, e.g. a minimally invasive sampling procedure.
Ann‐Marie Garzinsky, Andreas Thomas, Sven Guddat, Christian Görgens, Josef Dib, Mario Thevis   +5 more
wiley   +1 more source

Tiotropium/Olodaterol: A Review in COPD [PDF]

Drugs, 2019
Tiotropium/olodaterol (Stiolto® Respimat®; Spiolto® Respimat®) is an inhaled fixed-dose combination of the long-acting muscarinic antagonist tiotropium bromide (hereafter referred to as tiotropium) and the long-acting β2-adrenergic agonist olodaterol. It is available in several countries, including the USA, Japan, China and those of the EU, where it is
openaire   +2 more sources

Therapeutic Success of Tiotropium/Olodaterol, Measured Using the Clinical COPD Questionnaire (CCQ), in Routine Clinical Practice: A Multinational Non-Interventional Study

International Journal of COPD, 2021
Arschang Valipour,1 Sergey Avdeev,2 Adam Barczyk,3 Valentina Bayer,4 Zvi Fridlender,5 Mariela Georgieva,6 Ondřej Kudela,7 Alexey Medvedchikov,8 Ramona Miron,9 Maria Sanzharovskaya,8 Virginija Šileikienė,10 Jurij Šorli,11 Marc Spielmanns,12 ...
Valipour A, Avdeev S, Barczyk A, Bayer V, Fridlender Z, Georgieva M, Kudela O, Medvedchikov A, Miron R, Sanzharovskaya M, Šileikienė V, Šorli J, Spielmanns M, Szalai Z   +13 more
doaj  

Reducing and managing chronic obstructive pulmonary disease exacerbations with tiotropium + olodaterol [PDF]

Current Medical Research and Opinion, 2020
The aim of this study was to review clinical evidence supporting the use of fixed-dose combination of tiotropium and olodaterol, a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA), respectively, as the initial and follow-up treatment choice in patients with chronic obstructive pulmonary disease (COPD) as per Global ...
Gerard Criner, Sean Duffy
openaire   +2 more sources

Correction to: Tiotropium/Olodaterol: A Review in COPD [PDF]

Drugs, 2019
The article Tiotropium/Olodaterol: A Review in COPD, written by Hannah.
openaire   +2 more sources

Experience of using double bronchodilation therapy in patients with COPD

Медицинский совет, 2021
Chronic obstructive pulmonary disease (COPD) is currently one of the most socially significant diseases that leads to a significant decrease in the daily activity and productivity of patients, as well as their rapid invalidization.
I. V. Demko, N. V. Gordeeva, A. Yu. Kraposhina, M. G. Mamaeva, I. A. Soloveva   +4 more
doaj   +1 more source

Health and functional status of tiotropium/olodaterol-treated patients with COPD: results from the AERIAL® non-interventional study

ERJ Open Research, 2021
Patients with COPD often have reduced physical activity, which can impair health status. Real-world data can provide valuable information on the health and functional status of patients with COPD treated with tiotropium/olodaterol.
Adrian Gillissen, Andrea Marseille, Dirk Skowasch, John Ritz, Muriel Mattiucci-Guehlke, Stefan Pabst, Timm Greulich, Rembert Koczulla   +7 more
doaj   +1 more source

Deprescribing drugs with anticholinergic effects in older patients with increased risk of dementia in the multicomponent intervention study AgeWell.de

British Journal of Clinical Pharmacology, Volume 91, Issue 12, Page 3489-3500, December 2025.
Aim Drugs with anticholinergic effects are often considered as potentially inappropriate medications, especially for older patients, and deprescribing such drugs may improve cognitive function. The aim was to investigate the effectiveness of counselling on drug risks as part of a multimodal intervention to prevent cognitive decline. Methods The AgeWell.
Laura K. Lepenies, Hanna M. Seidling, Alexander Pabst, Melanie Luppa, Juliane Döhring, Martin Williamson, Thomas Frese, Jochen Gensichen, Wolfgang Hoffmann, Hanna Kaduszkiewicz, Hans‐Helmut König, Jochen René Thyrian, Birgitt Wiese, Steffi G. Riedel‐Heller, David Czock   +14 more
wiley   +1 more source

Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score–matched cohort analysis

Respiratory Research, 2021
Background Escalation to triple therapy (long-acting muscarinic antagonist/β2-agonist, inhaled corticosteroid [ICS]) in chronic obstructive pulmonary disorder (COPD) is recommended for patients on LAMA/LABA combinations with frequent exacerbations and ...
Shigeo Muro, Masaru Suzuki, Shuhei Nakamura, Jocelyn Ruoyi Wang, Elizabeth M. Garry, Wataru Sakamoto, Sabrina de Souza   +6 more
doaj   +1 more source